NewAmsterdam Pharma is a biopharmaceutical company developing obicetrapib, an oral medication designed to lower LDL cholesterol in patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia whose cholesterol remains elevated despite existing therapies. The company addresses a substantial market need by offering a convenient, once-daily oral alternative to injectable therapies and other lipid-lowering drugs with more modest efficacy, targeting the millions of patients who have not reached their cholesterol goals with current treatments. NewAmsterdam plans to commercialize obicetrapib directly in the United States and has licensed European rights to a pharmaceutical partner, while pursuing additional partnerships in Japan, China, and other markets, generating revenue through product sales and milestone and royalty payments from licensees.